Evidence map›Paper›PMID 28219449›Full record

ArticleMolecular neurodegeneration2017

Ex vivo

Erik Portelius, Niklas Mattsson, Josef Pannee, Henrik Zetterberg, Magnus Gisslén, Hugo Vanderstichele, Eleni Gkanatsiou, Gabriela A N Crespi, Michael W Parker, Luke A Miles and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular neurodegeneration, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Erik PorteliusInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Niklas MattssonClinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Josef PanneeInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Henrik ZetterbergInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Magnus GisslénDepartment of Infectious Diseases, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Hugo VandersticheleADx Neurosciences, Gent, Belgium.
Eleni GkanatsiouInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Gabriela A N CrespiSt. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.
Michael W ParkerSt. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.
Luke A MilesSt. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.
Johan GobomInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden. johan.gobom@neuro.gu.se.ORCID 0000-0001-6193-6193
Kaj BlennowInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
Sahlgrenska University Hospital · SEThe University of Melbourne · AUUniversity of Gothenburg · SEADx NeuroSciences · BELund University · SESt Vincents Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProteolytic degradation of amyloid β (Aβ) peptides has been intensely studied due to the central role of Aβ in Alzheimer's disease (AD) pathogenesis. While several enzymes have been shown to degrade Aβ peptides, the main pathway of Aβ degradation in vivo is unknown. Cerebrospinal fluid (CSF) Aβ42 is reduced in AD, reflecting aggregation and deposition in the brain, but low CSF Aβ42 is, for unknown reasons, also found in some inflammatory brain disorders such as bacterial meningitis.

methodUsing

resultsThe Aβ peptide profile was stable in CSF samples from healthy controls but in CSF samples from patients with bacterial meningitis, showing increased leukocyte cell count,

conclusion

Indexed as

Mass SpectrometryAlzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAntibodies, Monoclonal, HumanizedBrainHumansOxygen IsotopesPeptide FragmentsProteolysisAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAntibodies, Monoclonal, HumanizedAPP protein, humanOxygen IsotopesPeptide FragmentssolanezumabAmyloid βCerebrospinal fluidInsulin-degrading enzymeMass spectrometryStable isotope labeling

Identifiers

PMID28219449
PMCPMC5317049
OpenAlexW2591268718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.